Cilta-cel demonstrates superior efficacy and durability in treating high-risk myeloma, balancing effectiveness with safety concerns for patients.

A recent trial reveals cemiplimab significantly reduces recurrence in high-risk cutaneous squamous cell carcinoma, setting a ...

Why didn’t you do a direct comparison between patients undergoing TP prostate biopsy and patients undergoing TRUS biopsy? Dr. Grummet: That was beyond the scope of our resources at the time, and our ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...